family with sequence similarity 162 member BGenealiases: C6orf189 · bA86F4.2
Q-omics provides the consensus-scored FAM162B profile across patient tissues and cancer cell-line models. FAM162B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM162B is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, FAM162B RNA expression shows 20,472 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, THCA, and LSCC as cancer lineages where FAM162B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM162B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM162B survival associations across molecular data types. FAM162B RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM162B RNA expression–survival associations across cancer types. High FAM162B expression shows unfavorable associations in KIRP, UVM, STAD and LUSC, but favorable associations in HNSC and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM162B RNA expression.
This table summarizes FAM162B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM162B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM162B shows lower tumor expression in THCA, KICH, LUAD, KIRP and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher FAM162B RNA expression in normal versus tumor tissue (log2 FC = −2.150, t-test p < 0.001).
This table shows molecular features associated with FAM162B in patient tissues and cancer cell lines. In patient samples, FAM162B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM162B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
